Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Application ...
Tags: Iroko Pharmaceuticals, FDA, ZORVOLEX, osteoarthritis pain
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Application ...
US-based Iroko Pharmaceuticals has entered into a $75m debt facility agreement with an affiliate of OrbiMed Advisors (OrbiMed) to support general business operations and the launch of Zorvolex (diclofenac). Zorvolex is the first and only ...
US-based iCeutica announced that its partner Iroko Pharmaceuticals has received the US Food and Drug Administration (FDA) approval to market ZORVOLEX (diclofenac) capsules, a non-steroidal anti-inflammatory drug (NSAID) that utilizes ...
Specialty pharmaceutical company Iroko Pharmaceuticals has announced the FDA acceptance for New Drug Application (NDA) filing of lower dose submicron Indomethacin, a non-steroidal anti-inflammatory drug. The proposed indication of the ...
Tags: FDA Acceptance, NDA Filing
The US Food and Drug Administration (FDA) has accepted to review Iroko Pharmaceuticals New Drug Application (NDA) for lower dose submicron diclofenac, a non-steroidal anti-inflammatory drug (NSAID), with a proposed indication of treatment ...
Tags: FDA, Pharmaceuticals, Medicine
Iroko Pharmaceuticals has launched a new corporate headquarters in Philadelphia's Navy Yard Corporate Center, US. The new facility will support increased workforce as the company moves ahead with five late-stage development programs to ...
Tags: drug candidates, drugs, NSAIDs, medications